Biohaven Ltd.
NYSE:BHVNBiotechnology
-$0.22 today
- Market cap
- $2.06B
- Beta
- 3.31
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$4.39
Volume 3.26M
Average 2.47M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Biohaven Ltd.
NYSE:BHVN
Intrinsic Alpha fair value
Locked
Current Price
$13.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A12 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
AbCellera Biologics Inc. NASDAQ:ABCL | $3.75B | $11.49 | Not rated | -11.4 | +207.04% |
Xeris Biopharma Holdings, Inc. NASDAQ:XERS | $3.04B | $16.66 | Undervalued | 98.7 | +142.98% |
Pharvaris N.V. NASDAQ:PHVS | $2.34B | $33.36 | Not rated | -11.0 | +30.83% |
Celldex Therapeutics, Inc. NASDAQ:CLDX | $2.26B | $28.83 | Not rated | -7.8 | +11.53% |
Immunome, Inc. NASDAQ:IMNM | $2.22B | $18.77 | Not rated | -9.1 | -5.14% |
Vera Therapeutics, Inc. NASDAQ:VERA | $2.03B | $28.10 | Not rated | -6.8 | -4.02% |
Zenas BioPharma, Inc. NASDAQ:ZBIO | $1.90B | $28.01 | Not rated | -2.5 | -28.13% |
Immunocore Holdings plc NASDAQ:IMCR | $1.55B | $29.94 | Not rated | -77.5 | -31.74% |
Intellia Therapeutics, Inc. NASDAQ:NTLA | $1.36B | $9.70 | Not rated | -4.6 | +18.41% |
Sionna Therapeutics, Inc. NASDAQ:SION | $150.63M | $3.33 | Not rated | -19.7 | -92.37% |
Continue the stock analysis
Jump to another research area for this company.